Dasatinib: all 282 studies that test it
Page 3 of 3. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.
- Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid LeukemiaWithdrawnNCT02680951Phase 1
- Hematopoietic Stem Cell Transplant Survivors StudyCompletedNCT02652052Phase 1
- Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
- Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade PineoblastomaCompletedNCT02596828Phase 2
- Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaCompletedNCT02523976Phase 2
- Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or OlderActive, not recruitingNCT02494882Phase 1
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid TumorsActive, not recruitingNCT02389309Phase 1
- Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular ResponseCompletedNCT02326311Phase 3
- Treatment-free Remission Accomplished With Dasatinib in Patients With CMLStatus unknownNCT02268370Phase 2
- Explore the Synergy of Combination TKI TherapyWithdrawnNCT02129166Phase 1
- Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous LeukemiaCompletedNCT02113319Phase 2
- Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain TumorsStatus unknownNCT02015728Not applicable
- Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)CompletedNCT02013648Phase 3
- Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate CancerActive, not recruitingNCT01990196Phase 2
- OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)CompletedNCT01916785Phase 2
- Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT01872442Phase 2
- Study of Dasatinib, Androgen Deprivation Therapy and RadiationWithdrawnNCT01826838Phase 1
- De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid LeukaemiaCompletedNCT01804985Phase 2
- Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic PhaseStatus unknownNCT01802450Phase 2
- Dasatinib and Crizotinib in Advanced CancerCompletedNCT01744652Phase 1
- Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)CompletedNCT01724879Phase 2
- Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate CancerStatus unknownNCT01685125Phase 2
- Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT01660971Phase 1
- Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)CompletedNCT01644773Phase 1
- Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic MalignanciesTerminatedNCT01643603Phase 1
- Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are MetastaticCompletedNCT01643278Phase 1
- Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.CompletedNCT01636908Not applicable
- Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop TrialStatus unknownNCT01627132Phase 2
- Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin LymphomaTerminatedNCT01609816Phase 1
- Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial CancerCompletedNCT01482728Early Phase 1
- Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk NeuroblastomaCompletedNCT01467986Phase 2
- Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid LeukaemiaCompletedNCT01460693Phase 3
- Dasatinib in Combination With Bevacizumab to Treat Advanced Solid TumorsCompletedNCT01445509Phase 1
- Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial CancerCompletedNCT01440998Phase 1
- Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib MesylateTerminatedNCT01426334Phase 1
- TORI 104 Pre-Surgical DasatinibWithdrawnNCT01410708Phase 2
- Effects of Gastric pH on the Pharmacokinetics of DasatinibCompletedNCT01398046Phase 1
- A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With DasatinibCompletedNCT01342679Phase 2
- Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic LeukemiaCompletedNCT01310010Phase 2
- Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With SurgeryCompletedNCT01234935Phase 2
- Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma PatientsTerminatedNCT01116128Phase 2
- Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory DiseaseStatus unknownNCT01051115Phase 2
- Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced MalignanciesCompletedNCT01015222Phase 1
- First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALLCompletedNCT01004497Phase 2
- Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)CompletedNCT00996723Phase 1
- Evaluation of Response of Dasatinib to Treat MastocytosisStatus unknownNCT00979160Phase 2
- Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic LeukemiaCompletedNCT00940524Phase 1
- XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + DasatinibCompletedNCT00920868Phase 1
- Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed GlioblastomaTerminatedNCT00895960Phase 1
- Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid LeukemiaTerminatedNCT00895297Phase 2
- Study of Erlotinib in Combination With DasatinibCompletedNCT00895128Phase 1
- Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic SyndromeCompletedNCT00892190Phase 1
- Study of Dasatinib and Bendamustine in Chronic Lymphocytic LeukemiaWithdrawnNCT00872976Phase 1
- A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid LeukemiaCompletedNCT00866736Phase 2
- Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid LeukemiaCompletedNCT00852566Phase 2
- Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)CompletedNCT00850382Phase 1/2
- A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic LeukemiaWithdrawnNCT00829647Phase 1/2
- Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00816283Phase 1
- Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC FamilyCompletedNCT00779389Phase 1
- Solid Tumors Using Ixabepilone and DasatinibCompletedNCT00717704Phase 1
- PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal CancerCompletedNCT00672295Phase 1
- Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By SurgeryCompletedNCT00662636Phase 1
- Dasatinib in Resectable Malignant Pleural MesotheliomaCompletedNCT00652574Phase 1
- Ph I Dasatinib + Erlotinib in Recurrent MGCompletedNCT00609999Phase 1
- Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00608361Phase 1
- A Phase I/Expansion Study of DasatinibTerminatedNCT00598091Phase 1
- Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal TumorsCompletedNCT00568750Phase 2
- FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal CancerCompletedNCT00501410Phase 1
- A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)TerminatedNCT00500006Phase 1
- Gemcitabine and Dasatinib in Advanced Solid TumorsCompletedNCT00429234Phase 1
- Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid MalignanciesCompletedNCT00388427Phase 1
- Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALLWithdrawnNCT00349518Phase 2/3
- Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00345826Phase 1
- Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in JapanCompletedNCT00337454Phase 1/2
- Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib MesylateCompletedNCT00316953Phase 1
- A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib MesylateCompletedNCT00298987Phase 2
- Study of Dasatinib in Patients With Advanced Solid TumorsTerminatedNCT00162214Phase 1
- BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic LeukemiaCompletedNCT00103701Phase 1
- Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT00101595Phase 2
- Phase I (PH I) Mad Refractory Solid Tumor StudyCompletedNCT00099606Phase 1
- BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib MesylateCompletedNCT00064233Phase 1